Press Releases

SAN DIEGO , April 28, 2016 /PRNewswire/ -- Biocept, Inc. (" Biocept ") (Nasdaq: BIOC) today announced a proposed registered public offering of its common stock and warrants, subject to market and other conditions. The offering is subject to market and other conditions, and there can be no assurance

SAN DIEGO , July 11, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC) (" Biocept "), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today provided an

Company launches blood-based 'liquid biopsy' to identify ROS1 rearrangement and better inform NSCLC treatment decisions

SAN DIEGO --(BUSINESS WIRE)--Jan. 12, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO Michael W.

Revenue-producing sample volume during 2015 increases by more than 30% each consecutive quarter to greater than 1,800 for the year

Focus on new market segments and strategies to drive growth SAN DIEGO , Feb. 20, 2019 /PRNewswire/ -- Biocept, Inc.  (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients

SAN DIEGO --(BUSINESS WIRE)--Jun. 28, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will be added to the Russell Microcap Index after the U.S. market opens today, June 28, 2021 .

Introduction of blood-based assay to detect androgen receptor expression builds on leading position in detecting and monitoring cancer through liquid biopsy

SAN DIEGO , April 28, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company specializing in oncology biomarker detection and monitoring through circulating tumor cells (CTCs) and cell-free circulating tumor DNA, today announced the launch of its clinical research

Biocept continues to expand and perform COVID-19 testing services using Thermo Fisher Scientific platform SAN DIEGO --(BUSINESS WIRE)--Nov. 22, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, now offers a single test that can detect